Abstract
This open-label, non-randomized, parallel-group trial investigated the pharmacokinetics of raltitrexed (Tomudex, formerly ZD1694) after a single intravenous dose of 3.0 mg m(-2), comparing eight cancer patients with mild to moderate renal impairment (creatinine clearance 25-65 ml min(-1)) with eight cancer patients with normal renal function (creatinine clearance >65 ml min(-1)). The primary end points were area under the plasma raltitrexed concentration-time curve from the start of the infusion to the last determined concentration (AUC(0-tldc)) and AUC to infinity (AUC(0-infinity)); secondary end points were peak concentrations of raltitrexed (Cmax) and elimination half-life (t(1/2gamma)). The groups were compared statistically using analysis of covariance. The AUCs were greater for patients with renal impairment than for patients with normal renal function (2452.2 compared with 1247.3 ng h ml(-1) for AUC(0-tldc) (ratio 1.97; 95% CI 1.36-2.84); 2961.5 compared with 1457.0 ng h ml(-1) for AUC(0-infinity) (ratio 2.03; 1.25-3.29). These differences were statistically significant (P = 0.002 and P = 0.008 for AUC(0-tldc) and AUC(0-infinity) respectively. Terminal half-life was longer for the renally impaired patients (271.2 compared with 143.3; P = 0.030). There was no significant statistical difference between the groups for Cmax (652.9 compared with 564.7 ng ml(-1) for patients with impaired and normal renal function respectively: ratio 1.16; 0.91-1.46; P = 0.204). There was a clear relationship between raltitrexed clearance and creatinine clearance. Adverse events, severe (WHO grade 3 or 4) toxicity and hospitalization due to adverse events were more frequent in the group with renal impairment. Therefore, a reduction in raltitrexed dose and increased interval between doses is recommended for patients with mild to moderate renal impairment.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Clarke S. J., Hanwell J., de Boer M., Planting A., Verweij J., Walker M., Smith R., Jackman A. L., Hughes L. R., Harrap K. R. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol. 1996 May;14(5):1495–1503. doi: 10.1200/JCO.1996.14.5.1495. [DOI] [PubMed] [Google Scholar]
- Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
- Gore M. E., Earl H. M., Cassidy J., Tattersall M., Mansi J., Seymour L., Azab M. A phase II study of Tomudex in relapsed epithelial ovarian cancer. Ann Oncol. 1995 Sep;6(7):724–725. doi: 10.1093/oxfordjournals.annonc.a059291. [DOI] [PubMed] [Google Scholar]
- Jackman A. L., Taylor G. A., Gibson W., Kimbell R., Brown M., Calvert A. H., Judson I. R., Hughes L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. 1991 Oct 15;51(20):5579–5586. [PubMed] [Google Scholar]
- Pazdur R., Meropol N. J., Casper E. S., Fuchs C., Douglass H. O., Jr, Vincent M., Abbruzzese J. L. Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Invest New Drugs. 1996;13(4):355–358. doi: 10.1007/BF00873144. [DOI] [PubMed] [Google Scholar]
- Smith I., Jones A., Spielmann M., Namer M., Green M. D., Bonneterre J., Wander H. E., Hatschek T., Wilking N., Zalcberg J. A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer. 1996 Aug;74(3):479–481. doi: 10.1038/bjc.1996.386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zalcberg J. R., Cunningham D., Van Cutsem E., Francois E., Schornagel J., Adenis A., Green M., Iveson A., Azab M., Seymour I. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J Clin Oncol. 1996 Mar;14(3):716–721. doi: 10.1200/JCO.1996.14.3.716. [DOI] [PubMed] [Google Scholar]